Spravato Billing Guide: Codes, Units, REMS, and Claim Workflow

This guide explains the core codes, units, REMS requirements, and claim workflow used in Spravato (esketamine) billing for U.S. providers, where billing teams commonly make mistakes, and how to reduce preventable denials. Use it as an operational billing guide, not legal, clinical, or coding advice. Always confirm current payer policy, MAC guidance, contract requirements, CPT/HCPCS updates, and medical necessity rules before submitting claims.

Quick Spravato Billing Summary

What Is Spravato?

Spravato is an esketamine nasal spray used for:

• Treatment-resistant depression in adults, as monotherapy or with an oral antidepressant
• Depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant

Spravato is administered in a healthcare setting under direct observation. It is not dispensed to the patient for home use. Because of risks such as sedation, dissociation, respiratory depression, abuse, and misuse, Spravato is subject to REMS requirements. This makes it more complex than routine psychiatry billing.

Why Spravato Billing Is Complex

Spravato billing is complex because a single treatment session may involve several moving parts:

• Drug acquisition or specialty pharmacy coordination
• Prior authorization
• REMS enrollment and documentation
• Direct observation of patient self-administration
• Post-administration monitoring
• Blood pressure monitoring
• Respiratory monitoring, including pulse oximetry
• Payer-specific code selection
• Correct unit calculation
• NDC reporting
• Claim follow-up and denial management

For behavioral health and psychiatry practices, Spravato often creates billing problems when the front-end workflow is not tightly controlled.

Spravato Dose and Unit Basics

Each Spravato nasal spray device delivers 28 mg of esketamine.

Common NDC References

When billing J0013, the unit count should generally match the number of milligrams administered, unless the payer gives different instructions.

2026 Spravato Billing Codes

Drug Codes

For non-Medicare payers, J0013 may be used when the provider is billing for the drug. However, payer policy controls whether J0013, G-codes, or an unclassified drug code should be submitted.

Medicare Combination Codes

For Medicare, Spravato billing commonly uses combination G-codes.

In practical terms:

These G-codes are used when the provider purchases Spravato through the appropriate channel and bills for both the drug and related service. Do not automatically bill J0013 with G2082 or G2083. That may create duplicate billing risk.

Service Codes: E/M and Prolonged Monitoring

There is no single universal CPT code that describes every Spravato REMS monitoring scenario. Billing depends on:

• Payer type
• Site of care
• Whether the provider purchased the drug
• Whether a REMS-certified pharmacy supplied the drug
• Whether the payer accepts G-codes
• Whether the payer allows separate E/M or prolonged service coding

Potential service code categories may include:

The billing team should not assume that E/M or prolonged service codes are automatically payable just because a 2-hour observation period occurred. Confirm payer policy first.

Spravato Billing Scenarios

Scenario 1: Medicare, Provider Buys and Bills Spravato

When a Medicare provider purchases Spravato from the appropriate source and bills for the drug and treatment service:

• Do not separately bill J0013 if the Medicare G-code includes the drug and service.
• Confirm Medicare Advantage plan rules because some plans may follow different benefit or authorization workflows.

Scenario 2: Commercial Payer, Provider Buys and Bills Spravato

For commercial payers, confirm the payer's preferred billing structure before treatment. Possible claim structure:

Commercial payers may require:

• Prior authorization
• NDC reporting
• Correct NDC format
• Drug units matching dose
• Specific place of service
• Specific modifiers
• Medical benefit or pharmacy benefit routing
• Clinical documentation proving treatment-resistant depression criteria

Scenario 3: REMS-Certified Pharmacy Supplies Spravato

When Spravato is supplied by a REMS-certified pharmacy, the provider may only be billing for professional services, not the drug. Possible billing structure:

• Do not bill the drug if it was supplied and billed by the pharmacy.
• Do not use G2082 or G2083 if the provider did not also provide the drug.

Scenario 4: Hospital Outpatient Department

Hospital outpatient billing may differ from physician-office billing.

Hospital outpatient departments should confirm revenue code, drug billing, pharmacy benefit, and payer-specific outpatient billing instructions before claim submission.

Spravato REMS Requirements That Affect Billing

Spravato is only available through a restricted REMS program. This matters because claim payment may depend on documentation that the treatment was performed in a compliant healthcare setting. Billing and RCM teams should check that the record supports:

• Certified healthcare setting
• Patient enrollment when required
• Direct observation of self-administration
• At least 2 hours of post-administration monitoring
• Respiratory monitoring, including pulse oximetry
• Blood pressure monitoring
• Clinical stability before discharge
• Transportation instructions
• REMS Patient Monitoring Form completion
• Adverse event documentation, if applicable

A claim can be coded correctly and still be vulnerable during payer review if the chart does not support REMS compliance and monitoring.

Documentation Checklist for Treatment Sessions

For each Spravato visit, documentation should support the drug, service, monitoring, medical necessity, and payer requirements.

Patient and Visit Details

• Patient name
• Date of birth
• Date of service
• Diagnosis
• Indication for Spravato
• Treatment phase: induction, optimization, or maintenance
• Prior authorization number
• Ordering provider
• Rendering or supervising provider
• Site of care

Drug Documentation

• Dose administered: 56 mg or 84 mg
• Number of devices used
• NDC
• Lot number, if tracked by facility workflow
• Expiration date, if required
• Drug acquisition route
• Drug waste or disposal documentation, if required
• Controlled substance handling record, if required

Administration Documentation

• Patient self-administered Spravato
• Self-administration occurred under direct observation
• Time administration started
• Time administration completed
• Number of devices used
• Rest interval between devices, if documented by protocol

Monitoring Documentation

• Baseline blood pressure
• Blood pressure around 40 minutes after dosing
• Additional blood pressure readings as clinically indicated
• Pulse oximetry
• Respiratory status
• Sedation assessment
• Dissociation assessment
• Adverse effects or “none observed”
• Clinical stability before discharge
• Time patient was cleared for discharge
• Total monitoring period

REMS and Safety Documentation

• REMS enrollment confirmation
• Patient Monitoring Form completed
• Patient advised not to drive or operate machinery until the next day after restful sleep
• Transportation plan confirmed
• Serious adverse event reporting, if applicable

Prior Authorization Checklist

Before the first Spravato session, confirm:

• Patient is an adult
• Diagnosis supports payer policy
• Treatment-resistant depression criteria are met, when applicable
• Prior antidepressant trials are documented
• Dates, duration, and response to prior antidepressant therapy are available
• Oral antidepressant requirement is addressed when applicable
• Provider and site meet REMS requirements
• Drug acquisition route is confirmed
• Benefit type is confirmed: medical benefit vs pharmacy benefit
• Required codes are confirmed
• Required units are confirmed
• NDC requirement is confirmed
• Authorization effective dates are confirmed
• Approved number of visits or units is documented
• Reauthorization requirements are known

For Spravato, prior authorization should not be treated as a one-time task. The billing team should track when the authorization expires and what documentation is required for continuation. Dedicated prior authorization support and eligibility and benefits verification give this step clear ownership before the first treatment session.

Common Spravato Denial Reasons

Structured denial follow-up turns these patterns into prevention. AR follow-up support, denial management, and medical billing support can categorize denials by payer and work them to resolution.

ICD-10 Considerations

Diagnosis coding must match the provider's documentation and payer medical necessity policy. Common diagnosis families involved in Spravato coverage include:

Do not code from a billing guide alone. The provider's assessment, diagnosis specificity, and payer coverage policy should drive final ICD-10 selection.

Important note: a prior CMS billing and coding article for esketamine listed certain diagnosis codes for G2082 and G2083, but that article is retired effective 12/18/2025. For dates of service after retirement, teams should verify current payer and MAC guidance instead of relying on the retired article.

Clean Claim Workflow for Spravato

A practical Spravato billing workflow should be built around front-end prevention.

1. Before Treatment

• Verify active insurance
• Confirm medical vs pharmacy benefit
• Check whether behavioral health carve-out applies
• Obtain prior authorization
• Confirm REMS enrollment and certified setting
• Confirm drug acquisition route
• Confirm payer-required codes
• Confirm NDC and unit requirements
• Document authorization details in the billing system

2. Day of Treatment

• Confirm patient eligibility
• Confirm authorization is still active
• Confirm dose
• Document drug details
• Document direct observation of self-administration
• Record vitals and monitoring
• Complete REMS documentation
• Confirm discharge readiness
• Confirm transportation plan

3. Before Claim Submission

• Match claim codes to payer policy
• Confirm correct units
• Confirm NDC
• Confirm place of service
• Confirm rendering provider
• Confirm authorization number
• Confirm whether drug should be billed by provider or pharmacy
• Check whether E/M or prolonged service is supported
• Hold claim if documentation is incomplete

4. After Claim Submission

• Track claim status
• Work rejections quickly
• Appeal denials with documentation
• Track denials by payer and root cause
• Update payer-specific billing rules
• Monitor authorization utilization and reauthorization dates

Example Billing Logic

Example A: Medicare, 84 mg Dose, Provider Buy-and-Bill

Do not separately bill J0013 when the applicable G-code includes the drug and related treatment session.

Example B: Commercial Payer, 56 mg Dose, Provider Buy-and-Bill

Example C: Commercial Payer, 84 mg Dose, Provider Buy-and-Bill

Example D: REMS-Certified Pharmacy Supplies Drug

Best Practices for Spravato Billing Teams

• Verify payer rules before the first treatment.
• Separate Medicare, Medicare Advantage, Medicaid, and commercial billing logic.
• Confirm whether the drug is provider-supplied or pharmacy-supplied.
• Do not bill the drug when a specialty pharmacy supplied it.
• Do not bill J0013 with G2082 or G2083 unless payer guidance clearly allows it.
• Match J0013 units to administered milligrams.
• Confirm NDC requirements.
• Track prior authorization dates and approved units.
• Build a Spravato-specific claim checklist.
• Keep REMS forms organized and retrievable.
• Review denials by payer every month.
• Train staff on documentation gaps before claims go out.

For practices that offer Spravato, the billing risk is usually not one single code. The bigger issue is workflow control. A medical virtual assistant can own the authorization, REMS, and units log so nothing is billed beyond approval. Teams weighing in-house build vs. support can use the Billing In-House Readiness Grader or the Medical Virtual Assistant ROI Calculator.

Frequently Asked Questions

Disclaimer: This guide is provided for general operational reference only and is not legal, compliance, clinical, or coding advice. Spravato billing rules vary by payer, benefit type, drug acquisition route, and site of care. CPT and HCPCS codes, unit definitions, NDC requirements, REMS requirements, and coverage policies change. Always confirm current payer policy, MAC guidance, contract requirements, CPT/HCPCS updates, medical necessity rules, and the current AMA CPT manual before submitting claims. RCM Staff is an independent service provider and is not affiliated with, endorsed by, or certified by the AMA, CMS, FDA, the Spravato REMS program, Janssen/Johnson & Johnson, or any payer mentioned. Spravato is a registered trademark of its respective owner.